Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Mar 1;184(3):265-274.
doi: 10.1001/jamainternmed.2023.7660.

Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes

Julie M Paik  1   2   3   4 , Helen Tesfaye  1 , Gary C Curhan  2   4 , Heidi Zakoul  1 , Deborah J Wexler  4   5 , Elisabetta Patorno  1   4
Affiliations

Sodium-Glucose Cotransporter 2 Inhibitors and Nephrolithiasis Risk in Patients With Type 2 Diabetes

Julie M Paik et al. JAMA Intern Med. .

Abstract

Importance: Type 2 diabetes (T2D) is associated with an increased risk of kidney stones. Sodium-glucose cotransporter 2 inhibitors (SGLT2is) might lower the risk of nephrolithiasis by altering urine composition. However, no studies have investigated the association between SGLT2i use and nephrolithiasis risk in patients receiving routine care in the US.

Objective: To investigate the association between SGLT2i use and nephrolithiasis risk in clinical practice.

Design, setting, and participants: This new-user, active comparator cohort study used data from commercially insured adults (aged ≥18 years) with T2D who initiated treatment with SGLT2is, glucagon-like peptide 1 receptor agonists (GLP-1RAs), or dipeptidyl peptidase 4 inhibitors (DPP4is) between April 1, 2013, and December 31, 2020. The data were analyzed from July 2021 through June 2023.

Exposure: New initiation of an SGLT2i, GLP-1RA, or DPP4i.

Main outcomes and measures: The primary outcome was nephrolithiasis diagnosed by International Classification of Diseases codes in the inpatient or outpatient setting. New SGLT2i users were 1:1 propensity score matched to new users of a GLP-1RA or DPP4i in pairwise comparisons. Incidence rates, rate differences (RDs), and estimated hazard ratios (HRs) with 95% CIs were calculated.

Results: After 1:1 propensity score matching, a total of 716 406 adults with T2D (358 203 pairs) initiating an SGLT2i or a GLP-1RA (mean [SD] age, 61.4 [9.7] years for both groups; 51.4% vs 51.2% female; 48.6% vs 48.5% male) and 662 056 adults (331 028 pairs) initiating an SGLT2i or a DPP4i (mean [SD] age, 61.8 [9.3] vs 61.7 [10.1] years; 47.4% vs 47.3% female; 52.6% vs 52.7% male) were included. Over a median follow-up of 192 (IQR, 88-409) days, the risk of nephrolithiasis was lower in patients initiating an SGLT2i than among those initiating a GLP-1RA (14.9 vs 21.3 events per 1000 person-years; HR, 0.69 [95% CI, 0.67-0.72]; RD, -6.4 [95% CI, -7.1 to -5.7]) or a DPP4i (14.6 vs 19.9 events per 1000 person-years; HR, 0.74 [95% CI, 0.71-0.77]; RD, -5.3 [95% CI, -6.0 to -4.6]). The association between SGLT2i use and nephrolithiasis risk was similar by sex, race and ethnicity, history of chronic kidney disease, and obesity. The magnitude of the risk reduction with SGLT2i use was larger among adults aged younger than 70 years vs aged 70 years or older (HR, 0.85 [95% CI, 0.79-0.91]; RD, -3.46 [95% CI, -4.87 to -2.05] per 1000 person-years; P for interaction <.001).

Conclusions and relevance: These findings suggest that in adults with T2D, SGLT2i use may lower the risk of nephrolithiasis compared with GLP-1RAs or DPP4is and could help to inform decision-making when prescribing glucose-lowering agents for patients who may be at risk for developing nephrolithiasis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Curhan reported receiving grants from the National Institutes of Health during the conduct of the study and personal fees as an employee of OM1 Inc, royalties from UpToDate, and grants from GlaxoSmithKline outside the submitted work. Dr Wexler reported receiving personal fees from Novo Nordisk outside the submitted work. Dr Patorno reported receiving grants to her institution from Boehringer Ingelheim outside the submitted work. No other disclosures were reported.

Similar articles

See all similar articles

Cited by

References

    1. Chewcharat A, Curhan G. Trends in the prevalence of kidney stones in the United States from 2007 to 2016. Urolithiasis. 2021;49(1):27-39. doi:10.1007/s00240-020-01210-w - DOI - PubMed
    1. Stamatelou K, Goldfarb DS. Epidemiology of kidney stones. Healthcare (Basel). 2023;11(3):424. doi:10.3390/healthcare11030424 - DOI - PMC - PubMed
    1. Litwin MS, Saigal CS, eds; US Department of Health and Human Services; Public Health Service; National Institutes of Health; National Institute of Diabetes and Digestive and Kidney Diseases. Urologic Diseases in America. NIH Publication No. 12-7865. US Government Printing Office; 2012:486.
    1. Rule AD, Krambeck AE, Lieske JC. Chronic kidney disease in kidney stone formers. Clin J Am Soc Nephrol. 2011;6(8):2069-2075. doi:10.2215/CJN.10651110 - DOI - PMC - PubMed
    1. Alexander RT, Hemmelgarn BR, Wiebe N, et al. ; Alberta Kidney Disease Network . Kidney stones and kidney function loss: a cohort study. BMJ. 2012;345:e5287. doi:10.1136/bmj.e5287 - DOI - PMC - PubMed